Moving Toward Safer AAV Manufacturing: Evaluation Of Synthetic DNA As An Alternative To Plasmid DNA

By Celine Winkler, Associate Director, Viral Vectors Applications; Milena Pavlickova, Director of Platform Development, Blanka Awtani, Scientific Marketing Associate

Advances in adeno-associated virus (AAV) manufacturing are redefining how gene therapies are produced, with growing attention on safety, scalability, and cost. Traditional plasmid DNA approaches, while foundational, introduce challenges including batch variability, complex purification, and the risk of unwanted DNA impurities being packaged into viral vectors. Emerging synthetic DNA technologies offer a compelling alternative by eliminating bacterial sequences and enabling a cleaner starting material.

Hairpin-structured synthetic DNA supports efficient transfection while reducing overall DNA input, helping streamline upstream workflows and lower production costs. At the same time, analytical data shows a dramatic reduction in contaminating backbone sequences, strengthening the safety profile of resulting AAV products. As demand for gene therapies accelerates, these innovations present a path toward more consistent, scalable, and regulatory-friendly manufacturing.

Explore the full insights to understand how next-generation DNA platforms are reshaping AAV production.